Diagnostic value of the L-dopa test
Migdalska, B.; Wiśniewska-Woźniak, T.; Baranowska, B.; Kasperlik-Zaluska, A.; Olesińska, J.
Endokrynologia Polska 27(3): 265-274
1976
ISSN/ISBN: 0423-104X PMID: 1278129 Document Number: 101356
Document emailed within 1 workday
Related Documents
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786Ruitton, A.; Locard, E.; David, M.; Longin, B. 1973: Simplified test of stimulation of immunoreactive growth hormone (HGH-IR) by L-dopa: value as a screening test Archives Francaises de Pediatrie 30(7): 725-733
Vasil'ev, V.N.; Chugunov, V.S. 1983: Test with 0.1g L-DOPA in clinical neuroses and neurosis-like states Voprosy Meditsinskoi Khimii 29(3): 119-124
Blaim, A.; Kulesza, B.; Palńska-Cudnoch, M. 1976: L-DOPA test in differential diagnosis of growth deficiency in children Materia Medica Polona. Polish Journal of Medicine and Pharmacy 8(1): 26-30
Gouret, C.; Raynaud, G. 1973: L-DOPA jumping test in mice: its use in the study of antagonistic psychotropic drugs Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 167(10): 1360-1366
Schaaf, J.; Schaal, E. 1971: Comparative studies on the diagnostic value of the cornea test, the nose test, and the mouth test in the diagnosis of rabies, performed on rabies-positive necropsy material Deutsche Tierärztliche Wochenschrift 78(12): 341-346
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Badalian, L.O.; Temin, P.A.; Grinio, Z.N.; Amanova, Z.N.; Sadovskaia, I.E. 1985: Effect of the test with the drug Nakom on the dynamics of excretion of catecholamines and DOPA in children with Duchenne's progressive muscular dystrophy Pediatriia 5: 54-55
Kathke, N. 1971: Urobilinogen detection with test sticks. a practical diagnostic test, especially for mass examinations Münchener Medizinische Wochenschrift 113(24): 916-918
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Nierenberg, A.A.; Feinstein, A.R. 1988: How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test JAMA 259(11): 1699-1702